Annexon Inc ANNX shares are trading lower by some 57.16% to $2.96 Thursday morning. The company announced topline results from its ARCHER Phase 2 trial of ANX007 in patients with geographic atrophy (GA).
What Happened?
Annexon says ANX007 was generally well tolerated as both a monthly and every-other-month treatment.
The company also says ANX007 was “generally well-tolerated,” noting there were three cases of endophthalmitis or inflammation on the inner shield of the eye, but they were found to be administration-related, not treatment-related.
The six-month off-treatment follow-up period of the ARCHER Phase 2 trial is ongoing, and Annexon plans to report the final results following the study conclusion...Read More
According to data from Benzinga Pro, ANNX has a 52-week high of $7.65 and a 52-week low of $2.15.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
